Previous 10 | Next 10 |
Chiasma (CHMA) +39% on Q1 results.Athenex (ATNX) +31% on Kuur Therapeutics acquisition.Ault Global Holdings (DPW) +30% on preliminary Q1 results.iBio (IBIO) +26% after resolving Fraunhofer USA lawsuitBig 5 Sporting Goods Corporation (BGFV) +22% on Q1 results.DAVIDsTEA...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning and welcome to the halfway point of the week, investors! Here at InvestorPlace , we’re starting the day off like we always do with a look at the biggest pre-market stock movers. Join us as we list out t...
Gainers: Cocrystal Pharma (COCP) +157%.BioLineRx (BLRX) +75%.Reed's (REED) +36%.Neuronetics (STIM) +25%.Shineco (TYHT) +24%.Domtar (UFS) +18%.Arconic (ARNC) +17%.Huttig Building Products (HBP) +15%.Village Bank and Trust Financial (VBFC) +15%.Precipio (PRPO) +13%.Losers: ChemoC...
3 Reddit Penny Stocks to Watch as the Crypto Hype Continues With penny stocks, outside factors can have a large impact on what occurs throughout the market. This could be something as simple as news or even DogeCoin hitting an all-time high. This is referred to as speculation and is the...
Gainers: Cocrystal Pharma (COCP) +97%, BioLineRx (BLRX) +51%, Neuronetics (STIM) +21%, Shineco (TYHT) +20%, Precipio (PRPO) +14%.Losers: ChemoCentryx (CCXI) -38%, Regional Health Properties (RHE) -35%, Brooklyn ImmunoTherapeutics (BTX) -3...
BioLineRx (BLRX) soars 73% premarket in reaction to the announcement of positive top-line results from Phase 3 GENESIS trial evaluating Motixafortide, in combination with granulocyte colony stimulating factor (G-CSF, the standard of care in this indication), for hematopoietic stem-c...
BioLineRx (BLRX) +62% on positive top-line results from GENESIS phase 3 trial.Cocrystal Pharma (COCP) +40%.Huttig Building Products, Inc. (HBP) +26% on Q1 results.Vaxart (VXRT) +20% as its oral COVID-19 vaccine shows potential to offer promising solution against variants.Precip...
BioLineRx Announces Positive Top-Line Results from GENESIS Phase 3 Trial of Motixafortide in Stem-Cell Mobilization for Autologous Bone Marrow Transplantation in Multiple Myeloma Patients - Study met all primary and secondary endpoints with exceptionally high level of statistica...
Are These On Your List Of Penny Stocks To Buy Right Now? Everyone knows penny stocks can be risky. But with that higher risk comes the potential for higher rewards. Sure penny stocks under $0.50 that jump a quarter or more bring some big wins and great excitement to traders. How about t...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Thursday comes and with it, another busy day of trading begins. Before the opening bell rings, let’s examine the top pre-market movers that investors need to keep an eye on this morning. Source: f11photo/Shutterst...
News, Short Squeeze, Breakout and More Instantly...
BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD) PR Newswire - Investigator-initiated study in...
Orkla ASA ADR (ORKLY) is expected to report for Q1 2024 Cosmos Health Inc. (COSM) is expected to report $-0.14 for Q1 2024 Basilea Pharmaceutica AG Registered Shares (BPMUF) is expected to report for Q1 2024 DCC Plc (DCCPF) is expected to report for Q4 2024 Datatec Ltd ADR (DTTLY)...
BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting PR Newswire New analysis of biopsy samples demonstrate...